Germany, SwitzerlandGermany

Athelas, Combinature merge with Singapore-based Merlion

16.09.2006

Berlin/Geneva – The Singapore-based natural product specialist MerLion has bought two European firms. Together with the merger, the company will receive funding of a19.5 million. With Athelas, MerLion will have access to the company’s diVi antibiotic discovery platform.
“We wouldn’t have gotten such a large round in Germany”, said Dr. Harald Labischinski, former CEO of Combinature and now CSO of MerLion. Already in May, Labischinski announced the first closing of a a2.75 million – but a demand of a1.25 million, to satisfy his company’s capital needs, remained. After the merger, Combinature will be the drug discovery subsidiary of MerLion. Two antibiotic drug candidates will reach the clinic this year. MerLion CEO Tony Buss said that his company will be financed for the coming two years and anticipates an IPO within the next two years.

GermanyGermany

07.03.2012

The first of February marked a milestone for Leverkusen-based Bio­frontera AG in more ways than one. It was the first day that Ameluz, the firm’s first approved product, could be sold in German pharmacies. It was also the date...

GermanyGermany

07.03.2012

Darmstadt – German pharmaceutical and chemical company Merck KGaA has set a downbeat tone for 2012. CEO Karl-Ludwig Kley said the recently launched cost-cutting programme and tough economic conditions will weigh on profits this...

GermanyGermany

05.03.2012

Mainz/Leuna – Two biotech concepts were amongst the winners of the recent third round of the Excellence Cluster initiative, which is funded by the German Ministry for Research. In Mainz the champagne corks popped especially loud...

GermanyGermany

05.03.2012

German Merck KGaA has closed a licencing agreement with US-based Threshold Pharmaceuticals Inc. The cooperation centres around the hypoxia­-activated drug TH-302, which is currently being studied in a global Phase III study....

GermanyGermany

29.02.2012

Munich – Looking back with satisfaction and bent on a prize for good behaviour, German biopharmaceutical company Wilex AG reported yesterday on the fiscal year 2011 and outlined the shores in sight. The 2011 total revenue was...

GermanyGermany

17.02.2012

Brussels – European cartilage researchers intensify their cooperation. The 'gristle network' comprises scientists from Belgium, France, Germany and Luxembourg. Its members plan to meet regularly to exchange views and information...

27.01.2012

Thousand Oaks/Munich - Bling bling for blinatumomab. It is a compliment for the European life sciences scene and sad news at the same time. Amgen Inc., the world's largest biotechnology company, agreed to buy Micromet Inc., an...

GermanyGermany

20.01.2012

Martinsried - SHELTER is responsible for the fact that the stocks of 4SC behaved like a rodeo horse on Thursday. The shares rose in several stages up to 63%, only to settle at a mere 43% rise at the end of the day. SHELTER is a...

GermanyGermany

17.01.2012

Ludwigshafen – BASF Plant Science GmbH, the agrochemistry and biotech arm of the world-largest chemistry company, thinks that it has outstayed its welcome in Europe. Over the next two years, most of the green biotechnology...

GermanyGermany

10.01.2012

Munich - It is the accolade for Micromet. The German company, which is listed on the U.S. stock exchange, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the renowned US...

Displaying results 1 to 10 out of 454

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-germany/article/athelas-combinature-merge-with-singapore-based-merlion.html

Print Magazine

Product of the week

Products

Events

All Events

Partner-Events

Stock list

All quotes

TOP

  • FORMYCON9.74 EUR9.44%
  • CYTOS0.29 CHF3.57%
  • BAYER118.00 EUR3.42%

FLOP

  • MAGFORCE6.12 EUR-2.55%
  • SARTORIUS95.00 EUR-2.06%
  • ADDEX3.01 CHF-1.95%

TOP

  • CYTOS0.29 CHF81.2%
  • EPIGENOMICS5.25 EUR48.7%
  • STRATEC BIOMEDICAL48.65 EUR25.2%

FLOP

  • BIOFRONTERA2.53 EUR-12.8%
  • ADDEX3.01 CHF-8.8%
  • CO.DON2.53 EUR-8.0%

TOP

  • SANTHERA91.30 CHF2585.3%
  • CO.DON2.53 EUR141.0%
  • BB BIOTECH182.60 EUR64.6%

FLOP

  • CYTOS0.29 CHF-91.5%
  • 4SC0.94 EUR-46.0%
  • MOLOGEN7.39 EUR-41.1%

No liability assumed, Date: 23.11.2014

Current issue

All issues